fbpx
Wikipedia

Jason McLellan

January 01, 1970

Jason S. McLellan is a structural biologist, professor in the Department of Molecular Biosciences and Robert A. Welch Chair in Chemistry at The University of Texas at Austin[1] who specializes in understanding the structure and function of viral proteins, including those of coronaviruses.[2] His research focuses on applying structural information to the rational design of vaccines and other therapies for viruses,[3] including SARS-CoV-2, the novel coronavirus that causes COVID-19,[4] and respiratory syncytial virus (RSV).[5] McLellan and his team collaborated with researchers at the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center to design a stabilized version of the SARS-CoV-2 spike protein,[6][7][8][9] which biotechnology company Moderna used as the basis for the vaccine mRNA-1273,[10][11][12][13] the first COVID-19 vaccine candidate to enter phase I clinical trials in the U.S.[14] At least three other vaccines use this modified spike protein: those from Pfizer and BioNTech; Johnson & Johnson and Janssen Pharmaceuticals; and Novavax.[7][15]

Jason McLellan
NationalityAmerican
Education
Scientific career
FieldsStructural Biology
InstitutionsUniversity of Texas at Austin
Websitewww.mclellanlab.org

SARS-CoV-2 research edit

McLellan led a team from The University of Texas at Austin and the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center that produced the first molecular structure, or 3D atomic scale map, of the novel coronavirus’ spike protein, the protein that allows the virus to attach to and infect host cells.[6] The results were published online on February 19, 2020, in Science,[16] one of the world's top academic journals, and was highlighted on the cover of the 13 March 2020 print edition.[17]

The molecular structure provides a blueprint for scientists to learn to disrupt these processes through developing new treatments or vaccines.[18] Aubree Gordon, an associate professor of epidemiology at the University of Michigan who was not a part of the study was quoted by LiveScience as saying: "It's a very important step forward and may help in the development of a vaccine against SARS-COV-2."[18] The achievement was also highlighted as an important step towards a vaccine by the director of the National Institutes of Health, Francis Collins, in the NIH Director's Blog.[19]

McLellan and his team collaborated with researchers at the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center to design a stabilized version of the SARS-CoV-2 spike protein,[6][7][9] called S-2P or 2P, which biotechnology company Moderna used as the basis for the vaccine candidate mRNA-1273,[10][11][12][13] the first COVID-19 vaccine candidate to enter phase I clinical trials in the U.S.[14] The UT Austin and NIH teams filed a joint patent application on the mutated spike protein.[20]

Moderna's vaccine candidate, mRNA-1273, contains the genetic code for the stabilized version of the spike protein.[11] When a person is vaccinated with mRNA-1273, their own cells should theoretically produce these modified spike proteins, triggering their immune systems to develop antibodies against the actual coronavirus.[21]

The SARS-CoV-2 spike protein takes on one shape before entering a cell and another shape after, known as the prefusion and postfusion conformations.[22] Antibodies that recognize spike proteins in the prefusion shape are much more effective at preventing infection than antibodies that recognize spike proteins in the postfusion shape.[22] McLellan—along with his team members Daniel Wrapp and Nianshuang Wang, plus Barney Graham and Kizzmekia Corbett at NIAID's Vaccine Research Center—engineered the spike protein to stay in its initial shape so it can be recognized.[16] This, combined with Moderna's technology that uses messenger RNA to encode information about the virus, allows mRNA-1273 to trigger an immune response in vaccinated subjects.[11]

The stabilized spike protein developed by McLellan and his colleagues forms the basis of three COVID-19 vaccines that received emergency use authorization in the U.S.[7][15]

In May, 2020, he published[23] a new version of the stabilized SARS-CoV-2 spike protein called HexaPro that is currently being used as the basis for a new vaccine, NDV-HXP-S, which is undergoing trials in Brazil, Mexico, Thailand and Vietnam. These new vaccines are using a harmless avian virus that causes Newcastle Disease. This vaccine has the benefit of being easy to grow in chicken eggs, which are the basis of existing Influenza vaccines and are easier for developing nations to produce.[24]

McLellan and his team worked with pharmaceutical company Eli Lilly and Company to develop their monoclonal antibody treatment bamlanivimab (LY-CoV555),[25] which received emergency use authorization from the U.S. Food and Drug Administration in November 2020.[26] In April 2021, the EUA was revoked.[27]

In a separate but related project, McLellan and Daniel Wrapp worked with colleagues at the NIAID Vaccine Research Center and Ghent University to develop an antibody therapy for COVID-19 based on antibodies produced by a Winter (llama), a llama.[28] Initial tests indicate that their antibody blocks viruses that display the SARS-CoV-2 spike protein from infecting cells in culture. They reported their findings in Cell on May 5, 2020.[29] As of May 2020, the team was preparing to conduct preclinical studies in animals such as hamsters or nonhuman primates, with the hopes of next testing in humans.[30]

RSV research edit

Respiratory syncytial virus (RSV) is a very common, contagious virus that causes infections of the respiratory tract. RSV is the single most common cause of respiratory hospitalization in infants, reinfection remains common throughout the lifetime, and it is an important pathogen in all age groups.[31][32]

McLellan, along with Barney S. Graham and Peter Kwong of the National Institute of Allergy and Infectious Diseases' Vaccine Research Center, spearheaded the development of a protein subunit vaccine against RSV called DS-Cav1.[33] When the work began, McLellan was a postdoctoral researcher at VRC working in Graham's and Kwong's labs.

The antigen of this RSV vaccine, a stabilized version of the virus' F protein, was developed using structure-based vaccine design.[34][35][36] Structure-based vaccines are developed through a rational design process that uses information about the atomic structure of vulnerable parts of a pathogen to create a synthetic molecule that the human immune system recognizes as pathogenic and creates potent antibodies against.[37][38][39]

In a phase 1 clinical trial, DS-Cav1 was shown to be safe and to elicit "a robust boost in RSV F-specific antibodies and neutralising activity that was sustained above baseline for at least 44 weeks", according to a study published in April 2021 in The Lancet Respiratory Medicine.[40]

The first FDA-approved RSV vaccine, AREXVY (developed by GSK plc), uses a version of this antigen and was approved in May 2023 for adults aged 60 and older by the U.S. Food and Drug Administration (FDA).[41][42][5]

As of October 10, 2022, at least three other companies are testing candidate RSV vaccines based on stabilized prefusion F proteins in older adults in Phase 3 trials: Pfizer, Johnson & Johnson, and Moderna.[43][44][45]

Honors and awards edit

In 2020, Jason McLellan was one of seven researchers honored with a Golden Goose Award from the American Association for the Advancement of Science in recognition of COVID-19 research.[28][46] He was the 2020 recipient of the William Prusoff Memorial Award from the International Society for Antiviral Research, which honors a young scientist who has shown excellence in antiviral research and promise for future contributions to the field.[47] Previous honors include the Norman P. Salzman Memorial Award in Virology (2012),[48] the Charles H. Hood Foundation Child Health Research Award (2015),[49] the American Crystallographic Association Etter Early Career Award (2018)[50] and the Viruses Young Investigator in Virology Prize (2019).[51]

The Academy of Medicine, Engineering & Science of Texas awarded McLellan its 2022 Edith and Peter O'Donnell Award in Medicine.[52] Also in 2022, Dartmouth College awarded McLellan the inaugural McGuire Family Prize for Societal Impact,[53] and he was named a finalist for the Blavatnik National Award for Young Scientists.[54] In 2023, he was chosen for the NAS Award in Molecular Biology[55] and the Welch Foundation's Norman Hackerman Award in Chemical Research,[56] and named a Senior Member of the National Academy of Inventors.[57]

References edit

  1. ^ "UT CNS Directory: Jason McLellan". University of Texas at Austin College of Natural Sciences. Retrieved 14 Aug 2020.
  2. ^ "Jason S. McLellan". Google Scholar. Retrieved 29 May 2020.
  3. ^ . National Geographic. 1 February 2022. Archived from the original on February 2, 2022. Retrieved 2 Feb 2022.
  4. ^ "U.S. Scientists Take Key Step Towards Coronavirus Vaccine". U.S. News & World Report. 19 February 2020. Retrieved 29 May 2020.
  5. ^ a b "FDA-Approved RSV Vaccine Enabled by Work of UT Molecular Biologist". University of Texas at Austin. 4 May 2023. Retrieved 8 May 2023.
  6. ^ a b c "How structural biologists revealed the new coronavirus's structure so quickly". Chemical & Engineering News. 2 May 2020. Retrieved 4 June 2020.
  7. ^ a b c d "The tiny tweak behind COVID-19 vaccines". Chemical & Engineering News. 29 Sep 2020. Retrieved 30 Sep 2020.
  8. ^ "A gamble pays off in 'spectacular success': How the leading coronavirus vaccines made it to the finish line". Washington Post. 6 December 2020. Retrieved 9 Dec 2020.
  9. ^ a b Kramer, Jillian (31 December 2020). . National Geographic. Archived from the original on February 20, 2021.
  10. ^ a b "A coronavirus vaccine rooted in a government partnership is fueling financial rewards for company executives". Washington Post. 2 July 2020. Retrieved 2 July 2020.
  11. ^ a b c d "The First Shot: Inside the Covid Vaccine Fast Track". WIRED. 13 May 2020. Retrieved 29 May 2020.
  12. ^ a b "The sprint to solve coronavirus protein structures — and disarm them with drugs". Nature. 15 May 2020. Retrieved 29 May 2020.
  13. ^ a b Corbett, Kizmekia; Edwards, Darin; Leist, Sarah (5 Aug 2020). "SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness". Nature. doi:10.1038/s41586-020-2622-0. PMC 7301911. PMID 32577634.
  14. ^ a b "Trial of Coronavirus Vaccine Made by Moderna Begins in Seattle". New York Times. 16 March 2020. Retrieved 29 May 2020.
  15. ^ a b "A coronavirus vaccine is on the horizon, thanks to a key discovery by UT researchers". Austin American-Statesman. 10 Aug 2020. Retrieved 13 Aug 2020.
  16. ^ a b Wrapp, Daniel; Wang, Nianshuang; Corbett, Kizzmekia; Goldsmith, Jory; Hsieh, Ching-Lin; Abiona, Olubukola; Graham, Barney; McLellan, Jason (13 March 2020). "Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation". Science. 367 (6483): 1260–1263. Bibcode:2020Sci...367.1260W. doi:10.1126/science.abb2507. PMC 7164637. PMID 32075877.
  17. ^ "Science Magazine Cover". Science Magazine. Retrieved 4 June 2020.
  18. ^ a b "Coronavirus 'spike' protein just mapped, leading way to vaccine". LiveScience. 19 February 2020. Retrieved 4 June 2020.
  19. ^ "Structural Biology Points Way to Coronavirus Vaccine". National Institutes of Health. 3 March 2020. Retrieved 4 June 2020.
  20. ^ "Prefusion Coronavirus Spike Proteins and Their Use". National Institutes of Health. Retrieved 2 July 2020.
  21. ^ "Trials Are Underway For a Coronavirus Vaccine — But It Could Be a While Before You Can Get It". Discover Magazine. 20 March 2020. Retrieved 29 May 2020.
  22. ^ a b "What will it take to make an effective vaccine for COVID-19?". Chemical & Engineering News. 17 July 2020. Retrieved 13 Aug 2020.
  23. ^ Hsieh, Ching-Lin; Goldsmith, Jory A.; Schaub, Jeffrey M.; DiVenere, Andrea M.; Kuo, Hung-Che; Javanmardi, Kamyab; Le, Kevin C.; Wrapp, Daniel; Lee, Alison G.; Liu, Yutong; Chou, Chia-Wei; Byrne, Patrick O.; Hjorth, Christy K.; Johnson, Nicole V.; Ludes-Meyers, John; Nguyen, Annalee W.; Park, Juyeon; Wang, Nianshuang; Amengor, Dzifa; Lavinder, Jason J.; Ippolito, Gregory C.; Maynard, Jennifer A.; Finkelstein, Ilya J.; McLellan, Jason S. (18 September 2020). "Structure-based design of prefusion-stabilized SARS-CoV-2 spikes". Science. 369 (6510): 1501–1505. Bibcode:2020Sci...369.1501H. doi:10.1126/science.abd0826. PMC 7402631. PMID 32703906.
  24. ^ Zimmer, Carl. "Researchers Are Hatching a Low-Cost Coronavirus Vaccine". Retrieved April 4, 2021.
  25. ^ Jones, Bryan E.; et al. (1 October 2020). "LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection". bioRxiv 10.1101/2020.09.30.318972.
  26. ^ "Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19". U.S. Food and Drug Administration (Press release). 9 Nov 2020. Retrieved 4 Jan 2021.
  27. ^ "Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab". U.S. Food and Drug Administration (FDA) (Press release). 16 April 2021. Retrieved 16 April 2021.   This article incorporates text from this source, which is in the public domain.
  28. ^ a b Swenson, Haylie (December 2020). "2020 Golden Goose Award: A Llama Named Winter". American Association for the Advancement of Science. Retrieved 23 March 2023.
  29. ^ Wrapp, Daniel; et al. (28 May 2020). "Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies". Cell. 181 (5): 1004–1015.e15. doi:10.1016/j.cell.2020.04.031. PMC 7199733. PMID 32375025.
  30. ^ "Hoping Llamas Will Become Coronavirus Heroes". New York Times. 6 May 2020.
  31. ^ Coultas JA, Smyth R, Openshaw PJ (October 2019). "Respiratory syncytial virus (RSV): a scourge from infancy to old age". Thorax. 74 (10): 986–993. doi:10.1136/thoraxjnl-2018-212212. hdl:10044/1/73848. PMID 31383776. S2CID 199449874.
  32. ^ Griffiths C, Drews SJ, Marchant DJ (January 2017). "Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment". Clinical Microbiology Reviews. 30 (1): 277–319. doi:10.1128/CMR.00010-16. PMC 5217795. PMID 27903593.
  33. ^ McLellan, JS, ... Graham, BS, Kwong PD (November 1, 2013). "Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus". Science. 342 (6158): 592–598. Bibcode:2013Sci...342..592M. doi:10.1126/science.1243283. PMC 4461862. PMID 24179220.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  34. ^ Cohen, Jon (November 1, 2013). "Structural Biology Triumph Offers Hope Against a Childhood Killer". Science. 342 (6158): 546–547. Bibcode:2013Sci...342Q.546C. doi:10.1126/science.342.6158.546-a. PMID 24179197.
  35. ^ Crank, MC, ... McLellan, JS, Ledgerwood, JE, Graham, BS, the VRC 317 Study Team (August 2, 2019). "A proof of concept for structure-based vaccine design targeting RSV in humans". Science. 365 (6452): 505–509. Bibcode:2019Sci...365..505C. doi:10.1126/science.aav9033. PMID 31371616.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link)
  36. ^ "Experimental Vaccine Against Respiratory Syncytial Virus (RSV) Elicits Strong Immune Response" (Press release). The University of Texas at Austin. August 1, 2019. Retrieved 2021-06-02.
  37. ^ Dormitzer, PR, Ulmer, JB, Rappuoli, R (2008). "Structure-based antigen design:a strategy for next generation vaccines" (PDF). Trends in Biotechnology. 26 (12): 659–667. doi:10.1016/j.tibtech.2008.08.002. PMC 7114313. PMID 18977045.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  38. ^ Graham, BS, Gilman, MSA, McLellan, JS (January 27, 2019). "Structure-Based Vaccine Antigen Design". Annual Review of Medicine. 70: 91–104. doi:10.1146/annurev-med-121217-094234. PMC 6936610. PMID 30691364.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  39. ^ Kwong, PD, DeKosky, BJ, Ulmer, JB (November 24, 2020). "Antibody-guided structure-based vaccines". Seminars in Immunology. 50: 101428. doi:10.1016/j.smim.2020.101428. PMID 33246736. S2CID 227191531.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  40. ^ Ruckwardt, TJ, ... Graham, BS (April 14, 2021). "Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial". Lancet Respiratory Medicine. 9 (10): 1111–1120. doi:10.1016/S2213-2600(21)00098-9. PMC 8487912. PMID 33864736.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  41. ^ "FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine" (Press release). U.S. Food and Drug Administration. May 3, 2023. Retrieved May 3, 2023.
  42. ^ "First vaccine targeting RSV wins FDA approval. More are coming". Washington Post. May 3, 2023. Retrieved May 3, 2023.
  43. ^ "The race to make vaccines for a dangerous respiratory virus". Nature. 10 Dec 2021. Retrieved 26 April 2022.
  44. ^ "For decades, fear and failure in the hunt for an RSV vaccine. Now, success". Washington Post. 10 Oct 2022. Retrieved 11 Oct 2022.
  45. ^ "This UT Scientist Helped Spare Millions From COVID-19. Now He's Unmasking Other Killer Viruses". Texas Monthly. 10 Oct 2022. Retrieved 13 Oct 2022.
  46. ^ "COVID-19 researchers recognized with 2020 Golden Goose Award for scientific contributions" (Press release). American Association for the Advancement of Science. 1 December 2020. Retrieved 23 March 2023.
  47. ^ "William Prusoff Memorial Award". International Society for Antiviral Research. Retrieved 4 June 2020.
  48. ^ "Norman P. Salzman Memorial Award and Symposium in Virology". Foundation for the National Institutes of Health. Retrieved 4 June 2020.
  49. ^ "Hood Foundation Alumni Directory" (PDF). Charles H. Hood Foundation. Retrieved 4 June 2020.
  50. ^ "ACA Award Descriptions". American Crystallographic Association. Retrieved 4 June 2020.
  51. ^ "Viruses Young Investigator in Virology Prize". Viruses. Retrieved 4 June 2020.
  52. ^ "TAMEST 2022 Edith and Peter O'Donnell Awards".
  53. ^ "Creator of breakthrough coronavirus technology to receive inaugural McGuire Prize". EurekAlert. May 2, 2022. Retrieved May 23, 2022.
  54. ^ "Recognizing America's Leading Innovative Scientists, the 2022 Blavatnik National Awards for Young Scientists Names 31 Finalists". Blavatnik Awards for Young Scientists. June 1, 2022. Retrieved February 6, 2023.
  55. ^ "NAS Award in Molecular Biology".
  56. ^ ""The Welch Foundation Announces 2023 Norman Hackerman Award Recipient"". January 23, 2023.
  57. ^ "NAI Welcomes 95 New Emerging Innovators"". February 14, 2023.

External links edit

  • "TWiV 714: The shape of spike with Jason McLellan". YouTube. Vincent Racaniello. January 31, 2021.
  • "Jason McLellan: "Structure-based Design of Vaccine Antigens for SARS-CoV-2". YouTube. HHMI Howard Hughes Medical Institute. April 29, 2021.

January 01, 1970
jason, mclellan, jason, mclellan, structural, biologist, professor, department, molecular, biosciences, robert, welch, chair, chemistry, university, texas, austin, specializes, understanding, structure, function, viral, proteins, including, those, coronaviruse. Jason S McLellan is a structural biologist professor in the Department of Molecular Biosciences and Robert A Welch Chair in Chemistry at The University of Texas at Austin 1 who specializes in understanding the structure and function of viral proteins including those of coronaviruses 2 His research focuses on applying structural information to the rational design of vaccines and other therapies for viruses 3 including SARS CoV 2 the novel coronavirus that causes COVID 19 4 and respiratory syncytial virus RSV 5 McLellan and his team collaborated with researchers at the National Institute of Allergy and Infectious Diseases Vaccine Research Center to design a stabilized version of the SARS CoV 2 spike protein 6 7 8 9 which biotechnology company Moderna used as the basis for the vaccine mRNA 1273 10 11 12 13 the first COVID 19 vaccine candidate to enter phase I clinical trials in the U S 14 At least three other vaccines use this modified spike protein those from Pfizer and BioNTech Johnson amp Johnson and Janssen Pharmaceuticals and Novavax 7 15 Jason McLellanNationalityAmericanEducationWayne State University in Detroit Michigan BS in Chemistry Johns Hopkins University School of Medicine in Baltimore Maryland PhD Biophysics National Institutes of Health Vaccine Research Center postdoctoral research Scientific careerFieldsStructural BiologyInstitutionsUniversity of Texas at AustinWebsitewww wbr mclellanlab wbr org Contents 1 SARS CoV 2 research 2 RSV research 3 Honors and awards 4 References 5 External linksSARS CoV 2 research editMcLellan led a team from The University of Texas at Austin and the National Institute of Allergy and Infectious Diseases Vaccine Research Center that produced the first molecular structure or 3D atomic scale map of the novel coronavirus spike protein the protein that allows the virus to attach to and infect host cells 6 The results were published online on February 19 2020 in Science 16 one of the world s top academic journals and was highlighted on the cover of the 13 March 2020 print edition 17 The molecular structure provides a blueprint for scientists to learn to disrupt these processes through developing new treatments or vaccines 18 Aubree Gordon an associate professor of epidemiology at the University of Michigan who was not a part of the study was quoted by LiveScience as saying It s a very important step forward and may help in the development of a vaccine against SARS COV 2 18 The achievement was also highlighted as an important step towards a vaccine by the director of the National Institutes of Health Francis Collins in the NIH Director s Blog 19 McLellan and his team collaborated with researchers at the National Institute of Allergy and Infectious Diseases Vaccine Research Center to design a stabilized version of the SARS CoV 2 spike protein 6 7 9 called S 2P or 2P which biotechnology company Moderna used as the basis for the vaccine candidate mRNA 1273 10 11 12 13 the first COVID 19 vaccine candidate to enter phase I clinical trials in the U S 14 The UT Austin and NIH teams filed a joint patent application on the mutated spike protein 20 Moderna s vaccine candidate mRNA 1273 contains the genetic code for the stabilized version of the spike protein 11 When a person is vaccinated with mRNA 1273 their own cells should theoretically produce these modified spike proteins triggering their immune systems to develop antibodies against the actual coronavirus 21 The SARS CoV 2 spike protein takes on one shape before entering a cell and another shape after known as the prefusion and postfusion conformations 22 Antibodies that recognize spike proteins in the prefusion shape are much more effective at preventing infection than antibodies that recognize spike proteins in the postfusion shape 22 McLellan along with his team members Daniel Wrapp and Nianshuang Wang plus Barney Graham and Kizzmekia Corbett at NIAID s Vaccine Research Center engineered the spike protein to stay in its initial shape so it can be recognized 16 This combined with Moderna s technology that uses messenger RNA to encode information about the virus allows mRNA 1273 to trigger an immune response in vaccinated subjects 11 The stabilized spike protein developed by McLellan and his colleagues forms the basis of three COVID 19 vaccines that received emergency use authorization in the U S 7 15 In May 2020 he published 23 a new version of the stabilized SARS CoV 2 spike protein called HexaPro that is currently being used as the basis for a new vaccine NDV HXP S which is undergoing trials in Brazil Mexico Thailand and Vietnam These new vaccines are using a harmless avian virus that causes Newcastle Disease This vaccine has the benefit of being easy to grow in chicken eggs which are the basis of existing Influenza vaccines and are easier for developing nations to produce 24 McLellan and his team worked with pharmaceutical company Eli Lilly and Company to develop their monoclonal antibody treatment bamlanivimab LY CoV555 25 which received emergency use authorization from the U S Food and Drug Administration in November 2020 26 In April 2021 the EUA was revoked 27 In a separate but related project McLellan and Daniel Wrapp worked with colleagues at the NIAID Vaccine Research Center and Ghent University to develop an antibody therapy for COVID 19 based on antibodies produced by a Winter llama a llama 28 Initial tests indicate that their antibody blocks viruses that display the SARS CoV 2 spike protein from infecting cells in culture They reported their findings in Cell on May 5 2020 29 As of May 2020 the team was preparing to conduct preclinical studies in animals such as hamsters or nonhuman primates with the hopes of next testing in humans 30 RSV research editRespiratory syncytial virus RSV is a very common contagious virus that causes infections of the respiratory tract RSV is the single most common cause of respiratory hospitalization in infants reinfection remains common throughout the lifetime and it is an important pathogen in all age groups 31 32 McLellan along with Barney S Graham and Peter Kwong of the National Institute of Allergy and Infectious Diseases Vaccine Research Center spearheaded the development of a protein subunit vaccine against RSV called DS Cav1 33 When the work began McLellan was a postdoctoral researcher at VRC working in Graham s and Kwong s labs The antigen of this RSV vaccine a stabilized version of the virus F protein was developed using structure based vaccine design 34 35 36 Structure based vaccines are developed through a rational design process that uses information about the atomic structure of vulnerable parts of a pathogen to create a synthetic molecule that the human immune system recognizes as pathogenic and creates potent antibodies against 37 38 39 In a phase 1 clinical trial DS Cav1 was shown to be safe and to elicit a robust boost in RSV F specific antibodies and neutralising activity that was sustained above baseline for at least 44 weeks according to a study published in April 2021 in The Lancet Respiratory Medicine 40 The first FDA approved RSV vaccine AREXVY developed by GSK plc uses a version of this antigen and was approved in May 2023 for adults aged 60 and older by the U S Food and Drug Administration FDA 41 42 5 As of October 10 2022 at least three other companies are testing candidate RSV vaccines based on stabilized prefusion F proteins in older adults in Phase 3 trials Pfizer Johnson amp Johnson and Moderna 43 44 45 Honors and awards editIn 2020 Jason McLellan was one of seven researchers honored with a Golden Goose Award from the American Association for the Advancement of Science in recognition of COVID 19 research 28 46 He was the 2020 recipient of the William Prusoff Memorial Award from the International Society for Antiviral Research which honors a young scientist who has shown excellence in antiviral research and promise for future contributions to the field 47 Previous honors include the Norman P Salzman Memorial Award in Virology 2012 48 the Charles H Hood Foundation Child Health Research Award 2015 49 the American Crystallographic Association Etter Early Career Award 2018 50 and the Viruses Young Investigator in Virology Prize 2019 51 The Academy of Medicine Engineering amp Science of Texas awarded McLellan its 2022 Edith and Peter O Donnell Award in Medicine 52 Also in 2022 Dartmouth College awarded McLellan the inaugural McGuire Family Prize for Societal Impact 53 and he was named a finalist for the Blavatnik National Award for Young Scientists 54 In 2023 he was chosen for the NAS Award in Molecular Biology 55 and the Welch Foundation s Norman Hackerman Award in Chemical Research 56 and named a Senior Member of the National Academy of Inventors 57 References edit UT CNS Directory Jason McLellan University of Texas at Austin College of Natural Sciences Retrieved 14 Aug 2020 Jason S McLellan Google Scholar Retrieved 29 May 2020 Powerful tools help scientists find a virus s weak spot National Geographic 1 February 2022 Archived from the original on February 2 2022 Retrieved 2 Feb 2022 U S Scientists Take Key Step Towards Coronavirus Vaccine U S News amp World Report 19 February 2020 Retrieved 29 May 2020 a b FDA Approved RSV Vaccine Enabled by Work of UT Molecular Biologist University of Texas at Austin 4 May 2023 Retrieved 8 May 2023 a b c How structural biologists revealed the new coronavirus s structure so quickly Chemical amp Engineering News 2 May 2020 Retrieved 4 June 2020 a b c d The tiny tweak behind COVID 19 vaccines Chemical amp Engineering News 29 Sep 2020 Retrieved 30 Sep 2020 A gamble pays off in spectacular success How the leading coronavirus vaccines made it to the finish line Washington Post 6 December 2020 Retrieved 9 Dec 2020 a b Kramer Jillian 31 December 2020 They spent 12 years solving a puzzle It yielded the first COVID 19 vaccines National Geographic Archived from the original on February 20 2021 a b A coronavirus vaccine rooted in a government partnership is fueling financial rewards for company executives Washington Post 2 July 2020 Retrieved 2 July 2020 a b c d The First Shot Inside the Covid Vaccine Fast Track WIRED 13 May 2020 Retrieved 29 May 2020 a b The sprint to solve coronavirus protein structures and disarm them with drugs Nature 15 May 2020 Retrieved 29 May 2020 a b Corbett Kizmekia Edwards Darin Leist Sarah 5 Aug 2020 SARS CoV 2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness Nature doi 10 1038 s41586 020 2622 0 PMC 7301911 PMID 32577634 a b Trial of Coronavirus Vaccine Made by Moderna Begins in Seattle New York Times 16 March 2020 Retrieved 29 May 2020 a b A coronavirus vaccine is on the horizon thanks to a key discovery by UT researchers Austin American Statesman 10 Aug 2020 Retrieved 13 Aug 2020 a b Wrapp Daniel Wang Nianshuang Corbett Kizzmekia Goldsmith Jory Hsieh Ching Lin Abiona Olubukola Graham Barney McLellan Jason 13 March 2020 Cryo EM Structure of the 2019 nCoV Spike in the Prefusion Conformation Science 367 6483 1260 1263 Bibcode 2020Sci 367 1260W doi 10 1126 science abb2507 PMC 7164637 PMID 32075877 Science Magazine Cover Science Magazine Retrieved 4 June 2020 a b Coronavirus spike protein just mapped leading way to vaccine LiveScience 19 February 2020 Retrieved 4 June 2020 Structural Biology Points Way to Coronavirus Vaccine National Institutes of Health 3 March 2020 Retrieved 4 June 2020 Prefusion Coronavirus Spike Proteins and Their Use National Institutes of Health Retrieved 2 July 2020 Trials Are Underway For a Coronavirus Vaccine But It Could Be a While Before You Can Get It Discover Magazine 20 March 2020 Retrieved 29 May 2020 a b What will it take to make an effective vaccine for COVID 19 Chemical amp Engineering News 17 July 2020 Retrieved 13 Aug 2020 Hsieh Ching Lin Goldsmith Jory A Schaub Jeffrey M DiVenere Andrea M Kuo Hung Che Javanmardi Kamyab Le Kevin C Wrapp Daniel Lee Alison G Liu Yutong Chou Chia Wei Byrne Patrick O Hjorth Christy K Johnson Nicole V Ludes Meyers John Nguyen Annalee W Park Juyeon Wang Nianshuang Amengor Dzifa Lavinder Jason J Ippolito Gregory C Maynard Jennifer A Finkelstein Ilya J McLellan Jason S 18 September 2020 Structure based design of prefusion stabilized SARS CoV 2 spikes Science 369 6510 1501 1505 Bibcode 2020Sci 369 1501H doi 10 1126 science abd0826 PMC 7402631 PMID 32703906 Zimmer Carl Researchers Are Hatching a Low Cost Coronavirus Vaccine Retrieved April 4 2021 Jones Bryan E et al 1 October 2020 LY CoV555 a rapidly isolated potent neutralizing antibody provides protection in a non human primate model of SARS CoV 2 infection bioRxiv 10 1101 2020 09 30 318972 Coronavirus COVID 19 Update FDA Authorizes Monoclonal Antibody for Treatment of COVID 19 U S Food and Drug Administration Press release 9 Nov 2020 Retrieved 4 Jan 2021 Coronavirus COVID 19 Update FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab U S Food and Drug Administration FDA Press release 16 April 2021 Retrieved 16 April 2021 nbsp This article incorporates text from this source which is in the public domain a b Swenson Haylie December 2020 2020 Golden Goose Award A Llama Named Winter American Association for the Advancement of Science Retrieved 23 March 2023 Wrapp Daniel et al 28 May 2020 Structural Basis for Potent Neutralization of Betacoronaviruses by Single Domain Camelid Antibodies Cell 181 5 1004 1015 e15 doi 10 1016 j cell 2020 04 031 PMC 7199733 PMID 32375025 Hoping Llamas Will Become Coronavirus Heroes New York Times 6 May 2020 Coultas JA Smyth R Openshaw PJ October 2019 Respiratory syncytial virus RSV a scourge from infancy to old age Thorax 74 10 986 993 doi 10 1136 thoraxjnl 2018 212212 hdl 10044 1 73848 PMID 31383776 S2CID 199449874 Griffiths C Drews SJ Marchant DJ January 2017 Respiratory Syncytial Virus Infection Detection and New Options for Prevention and Treatment Clinical Microbiology Reviews 30 1 277 319 doi 10 1128 CMR 00010 16 PMC 5217795 PMID 27903593 McLellan JS Graham BS Kwong PD November 1 2013 Structure Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus Science 342 6158 592 598 Bibcode 2013Sci 342 592M doi 10 1126 science 1243283 PMC 4461862 PMID 24179220 a href Template Cite journal html title Template Cite journal cite journal a CS1 maint multiple names authors list link Cohen Jon November 1 2013 Structural Biology Triumph Offers Hope Against a Childhood Killer Science 342 6158 546 547 Bibcode 2013Sci 342Q 546C doi 10 1126 science 342 6158 546 a PMID 24179197 Crank MC McLellan JS Ledgerwood JE Graham BS the VRC 317 Study Team August 2 2019 A proof of concept for structure based vaccine design targeting RSV in humans Science 365 6452 505 509 Bibcode 2019Sci 365 505C doi 10 1126 science aav9033 PMID 31371616 a href Template Cite journal html title Template Cite journal cite journal a CS1 maint multiple names authors list link CS1 maint numeric names authors list link Experimental Vaccine Against Respiratory Syncytial Virus RSV Elicits Strong Immune Response Press release The University of Texas at Austin August 1 2019 Retrieved 2021 06 02 Dormitzer PR Ulmer JB Rappuoli R 2008 Structure based antigen design a strategy for next generation vaccines PDF Trends in Biotechnology 26 12 659 667 doi 10 1016 j tibtech 2008 08 002 PMC 7114313 PMID 18977045 a href Template Cite journal html title Template Cite journal cite journal a CS1 maint multiple names authors list link Graham BS Gilman MSA McLellan JS January 27 2019 Structure Based Vaccine Antigen Design Annual Review of Medicine 70 91 104 doi 10 1146 annurev med 121217 094234 PMC 6936610 PMID 30691364 a href Template Cite journal html title Template Cite journal cite journal a CS1 maint multiple names authors list link Kwong PD DeKosky BJ Ulmer JB November 24 2020 Antibody guided structure based vaccines Seminars in Immunology 50 101428 doi 10 1016 j smim 2020 101428 PMID 33246736 S2CID 227191531 a href Template Cite journal html title Template Cite journal cite journal a CS1 maint multiple names authors list link Ruckwardt TJ Graham BS April 14 2021 Safety tolerability and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS Cav1 a phase 1 randomised open label dose escalation clinical trial Lancet Respiratory Medicine 9 10 1111 1120 doi 10 1016 S2213 2600 21 00098 9 PMC 8487912 PMID 33864736 a href Template Cite journal html title Template Cite journal cite journal a CS1 maint multiple names authors list link FDA Approves First Respiratory Syncytial Virus RSV Vaccine Press release U S Food and Drug Administration May 3 2023 Retrieved May 3 2023 First vaccine targeting RSV wins FDA approval More are coming Washington Post May 3 2023 Retrieved May 3 2023 The race to make vaccines for a dangerous respiratory virus Nature 10 Dec 2021 Retrieved 26 April 2022 For decades fear and failure in the hunt for an RSV vaccine Now success Washington Post 10 Oct 2022 Retrieved 11 Oct 2022 This UT Scientist Helped Spare Millions From COVID 19 Now He s Unmasking Other Killer Viruses Texas Monthly 10 Oct 2022 Retrieved 13 Oct 2022 COVID 19 researchers recognized with 2020 Golden Goose Award for scientific contributions Press release American Association for the Advancement of Science 1 December 2020 Retrieved 23 March 2023 William Prusoff Memorial Award International Society for Antiviral Research Retrieved 4 June 2020 Norman P Salzman Memorial Award and Symposium in Virology Foundation for the National Institutes of Health Retrieved 4 June 2020 Hood Foundation Alumni Directory PDF Charles H Hood Foundation Retrieved 4 June 2020 ACA Award Descriptions American Crystallographic Association Retrieved 4 June 2020 Viruses Young Investigator in Virology Prize Viruses Retrieved 4 June 2020 TAMEST 2022 Edith and Peter O Donnell Awards Creator of breakthrough coronavirus technology to receive inaugural McGuire Prize EurekAlert May 2 2022 Retrieved May 23 2022 Recognizing America s Leading Innovative Scientists the 2022 Blavatnik National Awards for Young Scientists Names 31 Finalists Blavatnik Awards for Young Scientists June 1 2022 Retrieved February 6 2023 NAS Award in Molecular Biology The Welch Foundation Announces 2023 Norman Hackerman Award Recipient January 23 2023 NAI Welcomes 95 New Emerging Innovators February 14 2023 External links edit TWiV 714 The shape of spike with Jason McLellan YouTube Vincent Racaniello January 31 2021 Jason McLellan Structure based Design of Vaccine Antigens for SARS CoV 2 YouTube HHMI Howard Hughes Medical Institute April 29 2021 Retrieved from https en wikipedia org w index php title Jason McLellan amp oldid 1207775039, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.